(Aos1/Uba2) and a single E2 conjugating enzyme (Ubc9) have been identified in yeast and higher eukaryotes. In vitro, these are sufficient to modify a number of SUMO1 stricted to the nuclear compartment, SUMO1 would en-
ter the nucleus only in unconjugated form. Owing to the nate between active import of free or conjugated small size of SUMO1 (10 kDa), this could occur by active SUMO1. To investigate this, we carried out in vitro nuimport or by passive diffusion. Alternatively, if SUMO1 clear import assays (Figure 2 ). Consistent with our hymodification can also precede nuclear import, an enpothesis that SUMO1 conjugates may be the imported ergy-dependent mechanism would have to contribute to species in vivo, YFP-SUMO1 (1-97) was not actively SUMO1 intranuclear accumulation, because most target imported into the nucleus. Instead, it acccumulated at proteins are too large to enter by diffusion. To test this, the nuclear envelope in a pattern reminiscent of NPC we used three experimental approaches: first, transfecstaining. Similar results were obtained with FITC-labeled tion of wt and mutant SUMO1 lacking its C-terminal Gly SUMO (see Supplementary Figure S2 at http://www.cell. Gly motif; second, microinjection of wt SUMO1 into HeLa com/cgi/content/full/108/1/109/DC1). This rim staining cells with or without prior ATP depletion; and third, in is temperature sensitive, ATP-dependent, and saturable vitro nuclear import with digitonin-permeabilized HeLa (unlabeled SUMO1 reduces the signal by competition; cells. For all three experiments, we chose the same Figure 2B and data not shown). Interestingly, wheat reporter protein, SUMO1 fused to YFP. GFP-SUMO can germ agglutinin, which inhibits nuclear protein import replace endogeneous SUMO (pmt3) in fission yeast ( Taby BSA-NLS import was inhibited; data not shown). This As shown in Figure 1A , wt YFP-SUMO1 localizes exclusuggests that YFP-SUMO1 (1-97) accumulates at the sively in the nucleus after transfection, both diffusely cytoplasmic rather than the nuclear side of the NPC. distributed in the nucleoplasm and concentrated in nuBased on the ATP dependence, we speculated that YFPclear speckles. In contrast, YFP-SUMO1 (1-95) was dif-SUMO1 was forming isopeptide bonds with NPC-assofusely distributed throughout the cytoplasm and the nuciated proteins (thioester bonds could be excluded by cleus, remarkably similarly to the localization of YFP alone.
the resistance of the rim staining to 50 mM DTT; see This is consistent with previous findings with HA-tagged wt Supplementary Figure also rapidly and quantitatively modified by recombinant multiple sites. At 30 min, a faint higher molecular weight smear was apparent, perhaps indicative of additional Aos1/Uba2 and Ubc9 (see Okuma et al., 1999 , and below). To test whether RanBP2 can also be modified by conjugates. To investigate this further, we repeated the time course with an excess of enzymes and SUMO1 Aos1/Uba2 and Ubc9 alone, we generated two fragments of RanBP2 (depicted in Figure 3A ) that were re-( Figure 3C ). Under these conditions, RanGAP1 was again rapidly modified to a single species. In contrast, ported to contain the necessary determinants for SUMO1 modification as well as interactions with Gst-BP2 gave rise to multiple bands that increased in molecular weight during the time course. We infer from SUMO1*RanGAP1 and Ubc9 (Matunis et al., 1998; Saitoh et al., 1998). During the course of this study, we the molar ratios used in this reaction that each Gst-BP2 is modified by up to 25 molecules of SUMO1. As shown found that the smaller fragment (BP2⌬FG) is sufficient for the properties described below. Figure 3B shows a in Figure 3D , the extent to which RanBP2 is modified depends on the molar ratio of Gst-BP2 and SUMO1. In time course of RanGAP1 (top) and BP2⌬FG (bottom) modification with recombinant enzymes. Both proteins conclusion, RanBP2 and RanGAP1 can both be efficiently modified with recombinant E1 and E2 enzymes, are clearly modified in this reaction, with RanGAP1 being converted to a single modified species within just 5 min, but in addition, RanBP2 undergoes an unusual hypermodification that leads to depletion of SUMO1 from the and BP2⌬FG being modified somewhat more slowly at reaction mix. The high-molecular-weight RanBP2-SUMO1 SUMO1 species would be generated by Ulp1. In the second scenario (SUMO1 chains on Gst-BP2), the cleavconjugates could potentially form by attachment of single SUMO1 entities to multiple lysines in Gst-BP2 or age intermediates could also consist of SUMO1 oligomers. As is apparent from the cleavage pattern, recomcould reflect the formation of SUMO1 chains via SUMO1-SUMO1 isopeptide bond formation. To distinbinant Ulp1 rapidly generates species with apparent mobilities of ‫,03ف‬ ‫,54ف‬ and ‫06ف‬ kDa, indicative of guish between these two possibilities, we added the S. cerevisiae isopeptidase Ulp1 to hypermodified Gst-SUMO1 dimers, trimers, and tetramers, and the highmolecular-weight species disappear. This result is most BP2 ( Figure 3E ). In one scenario (multiple attachments of single SUMO1 molecules to Gst-BP2), only monomeric consistent with the interpretation that SUMO1 forms chains on RanBP2. SUMO2 is known to form chains E3-like activity. To address this, we relied on our observation that addition of SUMO1 stimulates modification of involving lysine 11 (Tatham et al., 2001 ). However, the SUMO1 chains on RanBP2 seem to be quite different, endogenous proteins in HeLa cytosol. RanGAP1 and RanBP2 are both present in HeLa cytosol; RanGAP1 since a mutant lacking amino acids 1-20 is still competent for chain formation (M. Schergaut, A.P., and F.M., because it is partially cytoplasmic, and RanBP2 due to the 5% mitotic cells present in asynchronously growing unpublished data).
cultures. If RanBP2 and/or its binding partner RanGAP1 were indeed required for SUMO1 conjugation, their imDepletion of RanGAP1/RanBP2 Complexes Removes SUMOylation Activity from Cytosol munodepletion should lead to a reduction in modification. We found that cytosol depleted with ␣ RanGAP1 As SUMO1-SUMO1 chain formation was induced in the presence of RanBP2, we speculated that it may have an antibodies shows a significantly reduced SUMO1 modi- fication pattern compared to control cytosol ( Figure 4A , contrast to RanGAP1, addition of 5 ng BP2⌬FG dramatically stimulated the appearance of SUMO1-modified lanes 2 and 4). To verify that this reduction in activity was caused by depletion rather than inactivation of facbands ( Figure 4C, lanes 7 and 8) . However, the SUMO1 pattern induced by BP2⌬FG is more intense than, and tors, we added back IP beads to RanGAP1-depleted cytosol. RanGAP1 IP beads but not IgG IP beads renot identical to, the pattern found in control cytosol. This is at least in part due to hypermodification of recomstored most of the activity ( Figure 4A , compare lanes 6 and 8). Depletion and readdition of RanGAP1 was veribinant BP2⌬FG and subsequent cleavage by endogenous isopeptidases (for comparison, see Figure 3E ). fied by immunoblotting with ␣ RanGAP1 antibodies (Figure 4A, bottom) . As expected, removal of RanGAP1 by immunoprecipitation did result in simultaneous depleRanBP2 Stimulates SUMO1 Modification of Sp100 To fully establish a role for RanBP2 as a stimulator of tion of RanBP2, but importantly neither Ubc9 nor Aos1 levels were affected ( Figure 4B ). This suggested that SUMO1 modification, we wanted to test its activity with a well-characterized SUMO1 target. For this we chose RanGAP1, RanBP2, or an unknown associated factor could be the stimulatory activity that was depleted by Sp100, a component of PML nuclear bodies (Sternsdorf et al., 1999). This protein seemed an ideal candidate for the IP. We explored this possibility by adding 5 ng RanGAP1 or BP2⌬FG to our depleted cytosol ( Figure  RanBP2 -stimulated SUMOylation. It contains a classical NLS, suggesting that it encounters RanBP2 on its way 4C). RanGAP1 was quantitatively modified by the depleted extract ( Figure 4C, bottom, lanes 5 and 6) , coninto the nucleus. Importantly, this NLS is essential for modification of Sp100 at lysine 297 in vivo (Sternsdorf firming that E1 and E2 enzymes were still active in the extracts. However, it did not induce modification of enet al., 1999). We set up an in vitro modification assay for Sp100 with recombinant E1 and E2 and tested the dogenous proteins, indicating that RanGAP1 is not the stimulatory activity ( Figure 4C, top, lanes 5 and 6) . In effect of BP2⌬FG or full-length RanBP2 from HeLa cells (provided in the form of ␣ RanGAP1 immunoprecipitates shown in Figure 5D , under conditions that allow efficient modification of Sp100, p53 is not SUMOylated either in described in Figure 4 ). As expected, Aos1/Uba2 and Ubc9 modify only marginal amounts of Sp100 (Figure the absence or presence of BP2⌬FG. Our recombinant p53 is competent for modification, as PIASy stimulates 5A). This can be significantly increased by the addition of either BP2⌬FG or full-length RanBP2, demonstrating p53 SUMOylation in similar experiments (A.P., S. Sachdev, R. Grossschedl, and F.M., unpublished data). We that RanBP2 indeed acts as a stimulator of modification. We then compared increasing amounts of BP2⌬FG for also tested four novel SUMO1 target proteins; two of these were better modified in the presence of BP2⌬FG, their effect on Sp100 modification (Figure 5B, left) . Already sufficient for strong stimulation was 1.5 nM and two were not affected (unpublished data). In summary, RanBP2 appears to work on several but not all BP2⌬FG (1 ng BP2⌬FG per 20 l reaction) . Surprisingly, increasing the concentration of BP2⌬FG actually de-SUMO1 targets. How this specificity is conferred remains to be resolved. creased its efficiency (compare 1 with 20 ng). One possible explanation for this inverse dose dependence is that excess BP2⌬FG competes with Sp100 for SUMO1. This RanBP2 Stimulates Transfer of SUMO1 between Ubc9 and Sp100 was confirmed in the next experiment ( Figure 5B, right) , where we repeated the experiment with a large excess The substrate specificity of RanBP2 already suggests that it participates in the transfer of SUMO1 from the of Sp100 and SUMO1 (1.5 g each of Sp100 and SUMO1, 5 ng BP2⌬FG, 10 ng Ubc9, and 150 ng Aos1/Uba2). In the E2 enzyme to its target. However, from our in vitro data, we could not exclude the possibility that it functions presence of BP2⌬FG, Sp100 was nearly quantitatively modified. RanBP2 stimulates Sp100 modification at its predominantly by enhancing SUMO1 transfer efficiency between the E1 and the E2 enzyme. We investigated physiological SUMO1 attachment site Lys 297 (Sternsdorf et al., 1999), as is shown in Figure 5C . A faint band visible the step at which it contributes by comparing rates of Ubc9-SUMO1 thioester bond formation in the absence in the K297R mutant migrates with different mobility than wt SUMO1*Sp100 and reflects a second, less efficient, or presence of BP2⌬FG ( Figure 6A ). SUMO1-Ubc9 thioesters are formed rapidly and efficiently with or without modification site. A hallmark for E3 ligases is that they confer substrate specificity. We therefore tested the ability BP2⌬FG. We reproducibly found a modest stimulation of thioester formation with BP2⌬FG, but the reason for of RanBP2 to stimulate SUMOylation of another wellknown SUMO1 target, the tumor suppressor p53. As this remains to be determined. However, the extremely and its ability to interact with preformed Ubc9-SUMO1 thioesters, we wanted to test whether RanBP2 functions Weissman, 2000). The minimal fragment used throughout this study (BP2⌬FG) contains seven cysteines but as a stable stoichiometric cofactor for Ubc9 or whether both proteins undergo cycles of association and dissocibears no resemblance to RING finger motifs. The only recognizable motif present in this domain is a short ation during Sp100 modification. In the first scenario, addition of a stoichiometric complex between RanBP2 internal repeat that is conserved in RanBP2s from different species. We generated a double mutant (Gstand Ubc9 should abolish the need for additional Ubc9 under all conditions. In the second scenario, free Ubc9 BP2⌬⌬Cys) in which one cysteine in each repeat was changed to serine. However, this double mutant still concentrations could influence the reaction rate by determining the efficiency of reassociation. We generated stimulated Sp100 modification ( Figure 6C ). Alkylating agents also did not inhibit RanBP2 function (data not two different complexes: a complex consisting just of BP2⌬FG and Ubc9 (F13), and a complex that also inshown), suggesting that free cysteine side chains are not required for its function. These findings open up cluded RanGAP1*SUMO1 to mimic the physiological situation at the NPC. We first tested 1 l of each complex the intriguing possibility that the mechanism of RanBP2 activity is different from ubiquitin E3 ligases.
(in F9 was an estimated amount of 15 ng BP2⌬FG, 5 5 or lanes 4 and 6) , indicating that the Ubc9 provided as part of either complex is Aos1/Uba2 ( Figure 7D ). catalytically active. We then repeated the experiment with less complex (0.3 l) and a much shorter incubation Discussion time (5 min). Strikingly, under these conditions, the reaction was clearly dependent on the addition of free Ubc9
RanBP2 Is an E3 SUMO1 Ligase We have demonstrated here that both full-length ( Figure 7C, bottom, compare lanes 3 and 5 or 4 and 6) . The different efficiencies of F9 and F13 appear to be RanBP2 and a 33 kDa fragment of RanBP2 strongly enhance SUMO1 modification of Sp100 in the presence due to different levels of BP2⌬FG and Ubc9 in these fractions, rather than a contribution by RanGAP1 (titraof recombinant E1 and E2 enzymes. RanBP2 clearly functions catalytically, as 5 ng BP2⌬FG are sufficient to tion experiments, data not shown). In summary, these findings are not consistent with a model in which Ubc9 induce conversion of a 300-fold molar excess of Sp100 ( Figure 5B, right) . Does this make RanBP2 a SUMO1 E3 and RanBP2 function as a stable complex, but rather suggest that Ubc9 and RanBP2 undergo cycles of assoligase? Ubiquitin E3 ligases are defined as "enzymes that bind, directly or indirectly, specific protein subat least, this is not the case, since hypermodified BP2⌬FG still stimulates Sp100 modification (data not strates and promote the transfer of ubiquitin, directly or indirectly, from a thioester intermediate to amide linkshown). Interestingly, both classes of SUMO1 E3 ligases seem to function on many different target proteins. We ages with proteins or polyubiquitin chains" (Hershko and Ciechanover, 1998). RanBP2 interacts directly with Ubc9 find that RanBP2 stimulates modification of three out of six tested proteins, and gene disruption of Siz1 and and promotes SUMO1 modification of Sp100 by stimulating transfer of SUMO1 from Ubc9 to Sp100. RanBP2 its relative Siz2 abolishes modification of most targets in yeast (Johnson and Gupta, 2001) . Whether this indicates does not interact directly with Sp100 in pull-down experiments (data not shown) but certainly does interact indithat SUMOylation involves fewer distinct E3-like factors than ubiquitination remains to be seen. rectly via Ubc9. Importantly, endogenous RanBP2 at the NPC will probably also interact with Sp100 by a second mechanism, due to its role as a docking site in nuclear RanBP2 May Coordinate SUMO1 Modification protein import. This interaction would be mediated by and Nuclear Import import receptors that interact with RanBP2 via FG repeat RanBP2 is part of the nucleocytoplasmic transport madomains directly flanking its E3-like domain (Figure 3; chinery ( no evidence for such a function. Alternatively, SUMOylaligases contain RING finger motifs essential for their tion at the NPC may serve as a mechanism to switch function. RanBP2 does not appear to fall into either proteins from a cytoplasmic to a nuclear mode of action. group. Treatment of the recombinant protein with alkylPlacing this at the NPC rather than into the nucleus ating agents does not inhibit its stimulatory effect on would be more effective and may be particularly imporSp100 modification (data not shown), suggesting that tant for SUMO1 targets that shuttle rapidly between both thioester bond formation is not required for its activity compartments. (due to RanBP2's rapid hypermodification, it has not What are the in vivo targets for RanBP2? For two been possible to directly test for the appearance of a reasons, we consider it possible that RanBP2 may serve thioester bond with SUMO1). On the other hand, the to modify many targets on their way into the nucleus. catalytic domain of RanBP2 (BP2⌬FG) lacks the consenFirst, most of the known SUMO1 targets contain a classisus sequence for RING finger domains (Jackson et al., cal NLS and will therefore encounter RanBP2 during 2000), and mutagenesis of two out of seven cysteines their translocation into the nucleus. Second, SUMOylahad no effect (no histidines are present in this domain).
tion of three out of six proteins was stimulated by Full-length RanBP2 may serve in part as an adaptor, BP2⌬FG in vitro (Figure 6 and unpublished data). Upon bringing together NLS-containing target proteins and translocation of modified targets into the nucleus, their Ubc9. This does not, however, explain the dramatic efSUMOylation status could be further regulated by isofect of the isolated BP2⌬FG domain. We consider it most peptidases as well as by E1, E2, and E3 modifying enlikely that BP2⌬FG functions allosterically by increasing zymes that reside inside the nucleus. Ubc9's affinity for specific targets or by facilitating
In conclusion, we have provided compelling evidence SUMO1 transfer to specific lysine residues. (1-97) was into adherent HeLa cells. ATP depletion was accom-SUMO1 purification involved bacterial lysis in 50 mM Tris/HCl (pH plished by incubating the cells for 30 min in glucose-free DMEM 8), 50 mM NaCl by sonification, preclearing of the 100,000 ϫ g (GIBCO) supplemented with 10% FBS, 6 mM 2-deoxyglucose, and supernatant with Q sepharose (SIGMA), concentration, and subse-10 mM sodium azide. Cells were kept at 37ЊC, and pictures were quent gel filtration. YFP-SUMO1 (1-97) purification involved lysis in taken at different times after injection using an inverted microscope 50 mM Tris/HCl (pH 8), 100 mM NaCl, 1 mM EDTA, ultracentrifugawith CCD camera (Olympus IX70). tion, ion exchange chromatography (HightrapQ, Amersham Pharmacia), and molecular sieving. Purification of SUMO E1 enzyme
